0
0
The Indian Council of Medical Research (ICMR) has initiated a crucial effort to develop indigenous monoclonal antibody (mAb) therapy against the Nipah virus (NiV), a zoonotic infection notorious for its high fatality rates and recurring outbreaks in India, particularly in Kerala. As per the latest Expression of Interest (EoI) issued by ICMR in November 2025, the apex medical research body is actively seeking partnerships with Indian biotechnology companies and manufacturers to jointly develop and manufacture monoclonal antibodies to counter Nipah virus infections. This move aims to ensure reliable and rapid access to treatment during future outbreaks, strengthening India’s preparedness against this emerging viral threat.
Understanding the Need for Indigenous Nipah Virus Therapy
Nipah virus is a highly lethal virus transmitted from animals to humans, with a case fatality rate ranging between 40% to 75%. Since its first reported outbreaks in India in 2001, recurrent incidents have presented significant public health challenges due to the absence of licensed vaccines or antiviral treatments. Globally, several vaccine candidates are in development, though none have yet received licensure. Therapeutically, monoclonal antibodies have emerged as the most promising candidate to treat Nipah virus infections, offering targeted viral neutralization by blocking virus entry into host cells.
Key Developments in Monoclonal Antibody Therapy
The most extensively studied monoclonal antibody candidate against NiV is m102.4, a fully human monoclonal antibody that targets the G glycoprotein of the Nipah virus. This glycoprotein is critical for the virus to attach and enter host cells by interacting with ephrin-B2/B3 receptors. By blocking this interaction, m102.4 prevents viral entry, effectively neutralizing the virus. Preclinical studies have demonstrated strong protective efficacy of m102.4 in animal models, and Phase 1 clinical trials have confirmed its safety profile.
Although definitive efficacy data from randomized human trials are still lacking, compassionate use protocols have administered m102.4 in Australia, and it was also provided during recent Nipah outbreaks in Kerala, India. These applications suggest promising potential while underscoring the urgent need for further clinical evaluation.
ICMR’s Role and Industry Collaboration Initiative
The ICMR-National Institute of Virology (ICMR-NIV) in Pune, equipped with advanced biosafety level 3 and 4 (BSL-3/4) laboratories, has been at the forefront of Nipah virus research and monoclonal antibody development. The institute specializes in virological surveillance, molecular characterization, and vaccine candidate development alongside conducting preclinical trials in suitable animal models.
The current EoI extends an invitation for Indian industry partners to collaborate in establishing an indigenous monoclonal antibody platform and manufacturing capabilities. This initiative is critical to reduce dependency on international sources, ensuring timely local availability of therapy to control outbreaks rapidly. Further, the ICMR has committed to providing expert guidance and technical support throughout all research and development phases, including laboratory testing and immune response evaluations in clinical trials (Phases I, II, and III).
Expert Insights on Nipah Virus Therapy Prospects
Dr. Anjali Sharma, an infectious disease specialist not involved in the ICMR project, notes: “The development of monoclonal antibodies like m102.4 represents a significant advancement in Nipah virus therapeutics. While vaccine development remains ongoing, monoclonal antibodies could serve as an immediate, targeted therapy during outbreaks. Indigenous manufacturing will be key to rapid response and treatment accessibility.”
Dr. Rajeev Menon, a virologist, emphasizes, “Although promising, monoclonal antibody therapy requires further robust large-scale clinical trials to establish efficacy definitively. The ICMR’s collaboration with industry is an excellent step towards making these therapies widely available, but it is vital to maintain rigorous evaluation standards.”
Implications for Public Health and Preparedness
If successful, an indigenously manufactured monoclonal antibody therapy against Nipah virus will mark a milestone in India’s pandemic preparedness and outbreak management protocols. Rapid deployment of this treatment during Nipah outbreaks could lower mortality rates by providing timely therapeutic intervention alongside standard supportive care. Moreover, local production enables cost reduction and sustainable stockpiling, critical for recurrent outbreak regions such as Kerala and northeastern states.
Limitations and Ongoing Challenges
Despite encouraging progress, challenges remain. The lack of comprehensive human efficacy data means monoclonal antibody therapies like m102.4 are yet to become standard treatment. Vaccine development, while advancing, may be years away from approval and wide distribution. Additionally, the evolving genetic diversity of Nipah virus strains poses potential obstacles for therapeutic effectiveness, necessitating continuous surveillance and update of antibody designs.
Conclusion
The ICMR’s proactive approach to develop indigenous monoclonal antibody therapy against Nipah virus through industry collaboration exemplifies India’s commitment to tackling this high-fatality threat with science-backed solutions. By leveraging cutting-edge research infrastructure and fostering public-private partnerships, the country aims to create a dependable, accessible therapeutic arsenal that could save many lives in future outbreaks. Ongoing careful clinical evaluation and surveillance will ensure therapies are both safe and effective.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
